BofA Securities has upgraded Vir Biotechnology (NASDAQ:VIR) to buy from neutral saying that the market is underestimating the company's phase 3 combo treatment for severe liver disease caused ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback